Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
Shots:
- The US FDA has approved Jylamvo (methotrexate) to treat pediatric with acute lymphoblastic leukemia (ALL) & polyarticular juvenile idiopathic arthritis (pJIA)
- Jylamvo is an oral solution (orange-flavored) of methotrexate, suitable for both adults and pediatric. It's used to treat various conditions, including rheumatological, dermatological, and oncological diseases
- Jylamvo was approved for treating adults with various conditions, including ALL, mycosis fungoides, r/r non-Hodgkin lymphoma, rheumatoid arthritis, and severe psoriasis
Ref: Businesswire | Image: Shorla Oncology
Related News:- Shorla Oncology Reports the Acquisition of Jylamvo from Therakind Targeting Oncology and Autoimmune Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
